Safety Reading Notes

Read safety context beside the research guide.

The CBG and safety/tolerability source set includes safety-context rows around safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: insufficient. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 39598860

Evidence class: insufficient

PubMed For Dummies Article

CBG and safety/tolerability Evidence Review: the long-form source walk-through

Quick read
  • CBG and safety/tolerability currently has 22 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 39598860
  • The evidence classes most visible in the row language are insufficient (11), mechanistic or pharmacological (8), preliminary human (2), and preclinical (1). PMID 39596290
  • The study-design language most visible in the row language is Cellular or in vitro study (7), Animal study (6), Narrative or expert review (5), and other mapped categories (3). PMID 11152013
  • The repeated topics are safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (22), which tells the reader where to start opening PubMed and DOI links. PMID 37947792

Start with the research question

CBG and safety/tolerability is built from 22 source-backed evidence row(s) and 22 research source(s). The current evidence classes read as insufficient (11), mechanistic or pharmacological (8), preliminary human (2), and preclinical (1), and the study-design language most often reads as Cellular or in vitro study (7), Animal study (6), Narrative or expert review (5), and other mapped categories (3). PMID 39598860

The row-level question is not simply whether CBG and safety/tolerability is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (22). PMID 39596290

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 40206058

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 38496308

Mechanistic evidence 0 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 36796712

Limits and uncertainty 33 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 40540228

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 39699828

Where this page has the most source density

The largest bucket surfaced for this page is safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 39598860

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 39596290

Bucket chapters: what the literature is circling

safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: insufficient

11 research sources 11 rows (541-559) Evidence class: insufficient

This bucket summarizes source-backed rows focused on safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: insufficient. It currently draws from 11 research source(s), so the exact study type matters. PMID 39598860

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 39598860

  • Evidence row 541

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative o... PMID 39598860

  • Evidence row 559

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse... PMID 32628766

safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: mechanistic or pharmacological

8 research sources 8 rows (542-562) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: mechanistic or pharmacological. It currently draws from 8 research source(s), so the exact study type matters. PMID 39596290

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 39596290

  • Evidence row 542

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study desig... PMID 39596290

  • Evidence row 562

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: safety, tolerabil... PMID 35246858

safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: preliminary human

2 research sources 2 rows (544, 546) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: preliminary human. It currently draws from 2 research source(s), so the exact study type matters. PMID 37947792

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 37947792

  • Evidence row 544

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, tolerability, adverse-... PMID 37947792

  • Evidence row 546

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, tolerability, adverse-... PMID 38496308

safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: preclinical

1 research source 550 Evidence class: preclinical

This bucket summarizes source-backed rows focused on safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe...: preclinical. It currently draws from 1 research source(s), so the exact study type matters. PMID 40523564

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 40523564

  • Evidence row 550

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure:... PMID 40523564

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (0 row(s)), and safety/tolerability context (22 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 39598860

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 39596290

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 40523564
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 35462234
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 40326034

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 39598860

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 39596290

Source-reading checklist for CBG and safety/tolerability

  1. Open the linked PubMed or DOI record. PMID 33562819
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 41548647
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 37414155
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 42107483
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 36497400

Source Notes

CBG and safety/tolerability source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 541

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 39598860

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
  2. Evidence row 542

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 39596290

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.
  3. Evidence row 543

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 11152013

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in clinical practice.
  4. Evidence row 544

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37947792

    Evidence class: preliminary human; Study design: Human clinical study. Source: A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS).
  5. Evidence row 545

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40206058

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system.
  6. Evidence row 546

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 38496308

    Evidence class: preliminary human; Study design: Human clinical study. Source: Safety study of cannabidiol products in healthy dogs.
  7. Evidence row 547

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36796712

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol.
  8. Evidence row 548

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40540228

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
  9. Evidence row 549

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 39699828

    Evidence class: insufficient; Study design: Animal study. Source: Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice.
  10. Evidence row 550

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40523564

    Evidence class: preclinical; Study design: Animal study. Source: Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner.
  11. Evidence row 551

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 35462234

    Evidence class: insufficient. Source: Non-psychotropic cannabinoids as inhibitors of TET1 protein.
  12. Evidence row 552

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40326034

    Evidence class: insufficient; Study design: Animal study. Source: Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis.
  13. Evidence row 553

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 33562819

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma.
  14. Evidence row 554

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 41548647

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study.
  15. Evidence row 555

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37414155

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?
  16. Evidence row 556

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42107483

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The impact of cannabigerol exposure on human endometrial stromal cells decidualization.
  17. Evidence row 557

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36497400

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.
  18. Evidence row 558

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
  19. Evidence row 559

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 32628766

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era.
  20. Evidence row 560

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36272108

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues.
  21. Evidence row 561

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 41934896

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models.
  22. Evidence row 562

    CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 35246858

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation.